Malaria Vaccines Market, by Agent (Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species), by Vaccine Type (Pre-Erythrocytic, Erythrocytic and Multi-antigen), by Distribution Channel (Public and Private) and by Region (North America, Latin America

Malaria Vaccines Market, by Agent (Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species), by Vaccine Type (Pre-Erythrocytic, Erythrocytic and Multi-antigen), by Distribution Channel (Public and Private) and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes. It is preventable and curable. Malaria vaccines are used to prevent the spread of malaria. The only approved vaccine, as of 2021, is RTS,S, known by the brand name Mosquirix. In October 2021, the World Health Organization (WHO) for the first time recommended the large-scale use of a malaria vaccine for children living in areas with moderate-to-high malaria transmission. Four injections of malaria vaccines are required for full protection.

Market Dynamics

Key players operating in the global malaria vaccine market are focusing on adoption of growth strategies such as agreements which are expected to drive market growth during the forecast period. For instance, in January 2021, GlaxoSmithKline (GSK), a science-led global healthcare company, PATH (Program for Appropriate Technology in Health), nonprofit global health organization based in Seattle, U.S., and Bharat Biotech (BBIL), is an Indian multinational biotechnology company announced the signing of a product transfer agreement for the malaria vaccine, RTS,S/AS01E. The agreement includes, transfer of manufacturing of the RTS,S antigen part of the vaccine and the grant of a license on all rights pertaining to the RTS,S/AS01 malaria vaccine to BBIL. GSK will retain the production of the adjuvant of the vaccine (AS01E) and will supply it to BBIL. Moreover, increasing research and development for malaria vaccine is expected to propel the global malaria vaccine market over the forecast period. For instance, in April 2021, scientists at the University of Oxford’s Jenner Institute announced that their Phase IIb trial of a candidate malaria vaccine achieved 77% efficacy in early stage trials – making it the first malaria vaccine to meet the WHO’s target of 75%. The Phase IIb trial of the vaccine candidate, R21, enrolled 450 children in Burkina Faso, one of the 10 countries with the highest cases of malaria and subsequent deaths.

Key features of the study:

• This report provides in-depth analysis of the global malaria vaccine market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Global Malaria vaccine Market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
• Key companies covered as a part of this study include GlaxoSmithKline, Nobelpharma, Sanaria, CellFree Sciences, VLP Therapeutics LLC, Sumaya Biotech, BioNTech, and Precigen, Inc
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The Global Malaria vaccine Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global malaria vaccine market.

Detailed Segmentation:

• Global Malaria vaccine Market, By Agent :
• Plasmodium Falciparum
• Plasmodium Vivax
• Anopheles Species
• Global Malaria vaccine Market, By Vaccine Type :
• Pre-Erythrocytic
• Erythrocytic
• Multi-antigen
• Global Malaria vaccine Market, By Distribution Channel :
• Public
• Private
• Global Malaria vaccine Market, By Region:
• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Country
• South Africa
• Central Africa
• North Africa
• Company Profiles
• GlaxoSmithKline.*
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Nobelpharma
• Sanaria
• CellFree Sciences
• VLP Therapeutics LLC
• Sumaya Biotech
• BioNTech
• Precigen, Inc

“*” marked represents similar segmentation in other categories in the respective section.